Eloxx Pharmaceuticals (ELOX) Misses Q4 EPS by 6c

Eloxx Pharmaceuticals (NASDAQ: ELOX) reported Q4 EPS of ($0.40), $0.06 worse than the analyst estimate of ($0.34).

“We are very pleased to be advancing ELX-02 in cystic fibrosis and look forward to reporting top line data from our Phase 2 clinical trial in the U.S. and Europe in 2019. New positive data for ELX-02 in cystic fibrosis patient-derived organoids with nonsense mutations consistently demonstrate dose responsive increases in FIS swelling, and functional CFTR which correlate with CFTRmRNA elevations to levels at or above wild-type, and we believe substantially de-risk our Phase 2 program. We look forward to presenting new important data on ELX-02 activity in restoring the CFTR protein at ECFS later this month,” said Robert E. Ward, Chairman and CEO of Eloxx Pharmaceuticals. “As we advance several new investigational product candidates from our library into development for inherited retinal diseases, we are grateful to have attracted Dr. Susan Schneider, a recognized expert in ophthalmology, to lead the team and also for the support of the Foundation Fighting Blindness.”

For earnings history and earnings-related data on Eloxx Pharmaceuticals (ELOX) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Bitmine reports 5.82 million ETH holdings, $11.4B total assets
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30